EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's EGFR Non-Small Cell Lung Cancer pipeline report depicts a robust space with 50+ EGFR Non-Small Cell Lung Cancer companies working to develop 50+ pipeline therapies for EGFR Non-Small Cell Lung Cancer treatment.
• The leading companies working in the EGFR Non-Small Cell Lung Cancer Market include Alpha Biopharma, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.
• Promising EGFR Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include AZD3759, AZD9291, BBT-207, Icotinib, naquotinib, midazolam, and others.
• April 2024: Daiichi Sankyo announced a study of Phase 2 clinical trials for Patritumab Deruxtecan (Fixed dose). This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

Request a sample and discover the recent advances in EGFR Non-Small Cell Lung Cancer Treatment Drugs @ EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the EGFR Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

EGFR Non-Small Cell Lung Cancer Overview
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain that regulates signaling pathways to control cellular proliferation.

Find out more about EGFR Non-Small Cell Lung Cancer Therapeutics Assessment @ EGFR Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

EGFR Non-Small Cell Lung Cancer Emerging Drugs Profile

AK112: Akeso Biopharma
AK112, is a first-in-class PD-1/VEGF bi-specific antibody, which is being developed by AKeso Biopharma. The drug is responsible for blocking PD-1 binding to PD-L1 and PD-L2 and also for blocking to VEGF binding to VEGF receptors. In November, 2022, AK112 has been granted as the Breakthrough Therapy Designation in China for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC). AK112, is currently being evaluated in phase III clinical trial for the treatment of Non-Squamous Non-small Cell Lung Cancer.

CLN-081: Cullinan Oncology
CLN-081 is a novel irreversible Epidermal Growth Factor Receptor (EFGR) inhibitor. It is administered through oral route, and is developed by Cullinan Oncology. The therapy is currently being evaluated in the Phase II for EGRF non-small cell lung cancer (NSCLC). In June 2022, Cullinan Oncology announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022. As per the terms of the agreement, the companies collaborated on the US development of CLN-081/TAS6417 for the treatment of a genetically defined subset of patients with non-small cell lung cancer (NSCLC).

BPI-361175: Betta Pharmaceuticals
BPI-361175 is a novel, oral, highly potent and selective 4th generation EGFR inhibitor developed by Betta Pharmaceutical Co., Ltd. The new chemical entity targets EGFR C797S mutation and other EGFR related mutations that are resistant to 3rd generation EGFR TKI in non-small cell lung cancer (NSCLC) and other solid tumors. It shows excellent inhibitory effect and selectivity in vitro assay and exhibits significant anti-tumor activity in a variety of xenograft models harboring EGFR C797S or other related mutations. The IND application of BPI-361175 has been approved by NMPA. Currently, the drug is the Phase I/II stage of its development for the treatment of Non-small Cell Lung Cancer.

JANX008: Janux Therapeutics
JANX008, is a TRACTr that targets Epidermal Growth Factor Receptor (EGFR), and is being developed by Janux Therapeutics for the treatment of various solid tumors including non-small cell lung cancer. According to preclinical studies, JANX008 showed potent cleavage dependent anti-tumor activity, with limited toxicities in healthy tissues or CRS. JANX008, is currently being evaluated in phase I clinical trial for the treatment of non-small cell lung cancer.

EGFR Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key EGFR Non-Small Cell Lung Cancer companies which are developing the EGFR Non-Small Cell Lung Cancer therapies. The EGFR Non-Small Cell Lung Cancer companies which have their EGFR Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Akeso Biopharma.

DelveInsight's EGFR Non-Small Cell Lung Cancer pipeline report covers around 42+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging EGFR Non-Small Cell Lung Cancer Pipeline Therapies @ EGFR Non-Small Cell Lung Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the EGFR Non-Small Cell Lung Cancer Pipeline Report
• Coverage- Global
• EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• EGFR Non-Small Cell Lung Cancer Companies- Alpha Biopharma, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.
• EGFR Non-Small Cell Lung Cancer Pipeline Therapies- AZD3759, AZD9291, BBT-207, Icotinib, naquotinib, midazolam, and others.

Dive deep into rich insights for new drugs for EGFR Non-Small Cell Lung Cancer Treatment, Visit @ EGFR Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. EGFR Non-Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. EGFR Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AK112: Akeso Biopharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CLN-081: Cullinan Oncology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. JANX008: Janux Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. EGFR Non-Small Cell Lung Cancer Key Companies
21. EGFR Non-Small Cell Lung Cancer Key Products
22. EGFR Non-Small Cell Lung Cancer- Unmet Needs
23. EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
24. EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
25. EGFR Non-Small Cell Lung Cancer Analyst Views
26. EGFR Non-Small Cell Lung Cancer Key Companies
27. Appendix

For further information on the EGFR Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to EGFR Non-Small Cell Lung Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://germanydennydones.websites.co.in/update/navigating-the-myopia-progression-market-insights/2460795
https://germanydennydones.freeescortsite.com/blog/detail/myopia-progression-market-size-and-outlook-analysis-report/
https://germanydennydones.ideascale.com/c/idea/93241
https://havensmith.mypixieset.com/blog/
https://germanydennydones.docs.apiary.io/#reference
https://comunidad.conocimientolibre.ec/profiles/germanydennydones/timeline?locale=en
https://paper.wf/germanydennydones/myopia-commonly-known-as-nearsightedness-affects-a-significant-portion-of-the
https://rant.li/germanydennydones/myopia-also-known-as-nearsightedness-is-a-prevalent-eye-condition
https://rant.li/germanydennydones/myopia-or-nearsightedness-is-a-refractive-error-of-the-eye-where-distant
https://kemono.im/germanydennydones/understanding-the-myopia-progression-market-insights-by-delveinsight
https://uconnect.ae/read-blog/40370
https://findaspring.org/members/dennydones9/
https://sketchfab.com/dennydones1
https://www.hoyolab.com/article/27093025
https://www.kfz-betrieb.vogel.de/community/user/ybhardwaj
https://pad.funkwhale.audio/s/z1sjb2E6Z
https://swaay.com/u/daviddollareusa/about/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.